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Understanding the antibody repertoire response to vaccination is critical for the rational design and evaluation of 
experimental vaccines.  Immune receptors comprise two chains encoded by separate mRNA strands and thus 
conventional NextGen sequencing fails to identify the native pairings encoded by individual lymphocytes.  To 
overcome this limitation, we are applying recent technical advances in high-throughput sequencing of complete 
antibodies (i.e., paired heavy and light chain sequencing) to generate a quantitative understanding of 
experimental vaccine performance and to accelerate vaccine design.  We apply repertoire-based metrics of 
vaccine-elicited antibodies to evaluate and select promising candidate immunogens for inducing HIV-1 
Envelope-specific VRC01-class antibodies.  The VRC01 class of broadly neutralizing antibodies have been 
observed in multiple individuals and targets the HIV CD4 binding site via a common recognition motif that 
requires specific features in both heavy and light chains (e.g., VH1-2 heavy chain V-gene and a short, 5 amino 
acid light chain CDR3).  We are using paired heavy and light chain sequencing to quantify the performance of 
various candidate HIV immunogens for inducing VRC01-class broadly neutralizing HIV antibodies in transgenic 
mouse models.  We are also elucidating the ontogeny of antibodies in vaccinated and naturally infected human 
subjects and animal models via interrogation of paired heavy and light chain antibody sequences and antibody 
synthesis/testing of promising clones, including experimental influenza vaccine trials and a Phase I Ebola 
vaccine trial.  These next-generation immunoanalytic approaches are providing detailed molecular feedback 
regarding experimental vaccine performance to accelerate vaccine design efforts against pathogens of major 
public health importance. 
 
 
